...
首页> 外文期刊>Neuropharmacology >8-OH-DPAT as a 5-HT(7) agonist: phase shifts of the circadian biological clock through increases in cAMP production.
【24h】

8-OH-DPAT as a 5-HT(7) agonist: phase shifts of the circadian biological clock through increases in cAMP production.

机译:8-OH-DPAT作为5-HT(7)激动剂:通过增加cAMP的产量来改变生物钟的生物钟。

获取原文
获取原文并翻译 | 示例
           

摘要

Neurons in the suprachiasmatic nucleus (SCN), the site of the endogenous biological clock in mammals, fire spontaneously, peaking in firing rate near ZT6 or at the midpoint of the light phase in a 12:12 light-dark cycle. In rat hypothalamic slices, tissue incubations with drugs can produce a shift in this daily rhythm, the magnitude of which is dependent upon dose and the time of treatment. Previous work with 8-OH-DPAT had noted its ability to produce a phase advance, an earlier occurrence of the peak in neuronal firing, when applied at ZT6. Activation of 5-HT(7) receptors was thought to be responsible for the shift, despite the clear preference of 8-OH-DPAT for 5-HT(1A) sites in terms of receptor binding affinity. In the present work, the actions of 8-OH-DPAT in SCN slices were confirmed and expanded to include additional dose-response and antagonist treatments. By itself, 8-OH-DPAT produced a concentration-dependent phase advance that was sensitive to co-application with 5-HT(7) antagonists (ritanserin, mesulergine, SB-269970), but not to 5-HT(1A) antagonists (WAY-100,635, UH-301). Assignment of the receptor mechanisms for the antagonists employed was accomplished in experiments measuring binding affinities and the generation of cAMP, the latter monitored in a HEK-293 cell line expressing the r5-HT(7) receptor and in tissue derived from rat SCN. The results indicate that the increases observed in cAMP levels are small but appear to be sufficient to produce a pharmacological resetting of the clock pacemaker. By aiding in the identification of the 5-HT receptor subtype responsible for the observed phase shifts and cAMP changes, 8-OH-DPAT represents an important pharmacological tool for 5-HT(7) receptor activation, essentially broadening its role as the prototypical 5-HT(1A) agonist to one combining these two receptor activities.
机译:哺乳动物上的内源性生物钟的位置,视交叉上神经核(SCN)中的神经元自发地发射,其发射速率在ZT6附近或在12:12的明暗周期的亮相中点达到峰值。在大鼠下丘脑片中,药物与组织的温育会导致这种每日节律发生变化,其变化幅度取决于剂量和治疗时间。以前使用8-OH-DPAT进行的研究表明,当应用于ZT6时,它具有产生相位超前的能力,这是神经元放电峰值的较早出现。 5-HT(7)受体的激活被认为是造成这种转变的原因,尽管就受体结合亲和力而言,8-OH-DPAT对于5-HT(1A)位点有明显的偏爱。在目前的工作中,SCN切片中的8-OH-DPAT的作用已得到确认并扩展到包括其他剂量反应和拮抗剂治疗。就其本身而言,8-OH-DPAT产生了一个浓度依赖性的相进展,该进展对与5-HT(7)拮抗剂(利坦色林,美舒乐精,SB-269970)共同应用敏感,但对5-HT(1A)拮抗剂不敏感。 (WAY-100,635,UH-301)。在测量结合亲和力和cAMP生成的实验中完成了所用拮抗剂的受体机制分配,后者在表达r5-HT(7)受体的HEK-293细胞系和大鼠SCN组织中进行了监测。结果表明,在cAMP水平上观察到的增加很小,但似乎足以使时钟起搏器恢复药理作用。通过帮助鉴定负责观察到的相移和cAMP变化的5-HT受体亚型,8-OH-DPAT代表了5-HT(7)受体激活的重要药理工具,从本质上扩展了其作为原型5的作用。 -HT(1A)激动剂结合了这两种受体活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号